ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Inclusion Criteria: * Age 4 to 55 (inclusive) * Clinical history of allergy to at least 1 of the foods contained in ADP101 * Experience dose-limiting symptoms at or below the 100-mg dose level to 1 or multiple food sources in ADP101 Exclusion Criteria: * Experience dose limiting symptoms at or below the 100 mg challenge dose level to more than 5 food sources contained in ADP101 * History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock within 60 days of screening * History of EoE, other eosinophilic gastrointestinal disease, chronic, recurrent or severe GERD, symptoms of dysphagia * Severe asthma * Mild or moderate asthma, if uncontrolled or difficult to control * History of mast cell disorder, including mastocytosis, urticaria pigmentosa or angioedema * History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) at risk of becoming unstable or requiring a change in chronic therapeutic regimen e.g. uncontrolled diabetes * History of cardiovascular disease, including hypertension requiring \> 2 antihypertensive medications * History of interstitial lung disease * History of celiac disease * Active autoimmune disease that has required systemic treatment within 3 months * Known malignancy that is progressing or has required active treatment within the past 3 years * Known history of HIV, known active hepatitis B infection or known active hepatitis C virus infection * Prior/concurrent therapies as follows: * beta-blockers, ACE inhibitors, ARBs or calcium channel blockers * regular steroid medication use * therapeutic antibody treatment currently or within the previous 6 months * any food immunotherapy currently or within the previous 12 weeks * In the build up phase of non-food immunotherapy * Residing at the same address as another subject (e.g. siblings) participating in this or any other OIT study * Develops dose-limiting symptoms to placebo during the Screening DBPCFC * Any other condition that might preclude safe participation in the study